{"name":"Astellas Pharma Europe B.V.","slug":"astellas-pharma-europe-b-v","ticker":"","exchange":"","domain":"","description":"Astellas Pharma Europe B.V. is a subsidiary of Astellas Pharma Inc., focusing on the research, development, and commercialization of innovative pharmaceuticals in various therapeutic areas. The company has a strong pipeline with several drugs in late-stage development and a portfolio of marketed products.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":600000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","revenue":600000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Hematology","slug":"hematology","revenue":600000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","indication":"Anemia in chronic kidney disease","status":"marketed","revenue":600000000}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":15,"colorKey":"immunology","drugs":[{"name":"ASP1707 single dose fed","genericName":"ASP1707 single dose fed","slug":"asp1707-single-dose-fed","indication":"Other","status":"phase_1"},{"name":"ASP1128","genericName":"ASP1128","slug":"asp1128","indication":"Other","status":"phase_2"},{"name":"ASP1707 multiple dose of dose levels 1-2","genericName":"ASP1707 multiple dose of dose levels 1-2","slug":"asp1707-multiple-dose-of-dose-levels-1-2","indication":"Other","status":"phase_1"},{"name":"ASP1707 multiple dose of dose levels 1-4","genericName":"ASP1707 multiple dose of dose levels 1-4","slug":"asp1707-multiple-dose-of-dose-levels-1-4","indication":"Other","status":"phase_1"},{"name":"ASP1707 single dose fasted","genericName":"ASP1707 single dose fasted","slug":"asp1707-single-dose-fasted","indication":"Other","status":"phase_1"},{"name":"ASP1707 single dose of dose levels 1 -7","genericName":"ASP1707 single dose of dose levels 1 -7","slug":"asp1707-single-dose-of-dose-levels-1-7","indication":"Other","status":"phase_1"},{"name":"ASP3652","genericName":"ASP3652","slug":"asp3652","indication":"Complement-mediated inflammatory disorders (Phase 2 development)","status":"phase_2"},{"name":"ASP6282","genericName":"ASP6282","slug":"asp6282","indication":"Other","status":"phase_1"},{"name":"ASP6294 Intravenous","genericName":"ASP6294 Intravenous","slug":"asp6294-intravenous","indication":"Other","status":"phase_1"},{"name":"ASP6294 Subcutaneous","genericName":"ASP6294 Subcutaneous","slug":"asp6294-subcutaneous","indication":"Other","status":"phase_1"},{"name":"ASP6858","genericName":"ASP6858","slug":"asp6858","indication":"Other","status":"phase_1"},{"name":"ASP7713","genericName":"ASP7713","slug":"asp7713","indication":"Other","status":"phase_1"},{"name":"Placebo to match mirabegron","genericName":"Placebo to match mirabegron","slug":"placebo-to-match-mirabegron","indication":"Placebo control for mirabegron trials in overactive bladder","status":"phase_3"},{"name":"Placebo to match solifenacin succinate","genericName":"Placebo to match solifenacin succinate","slug":"placebo-to-match-solifenacin-succinate","indication":"Placebo control for solifenacin succinate trials in overactive bladder","status":"phase_3"},{"name":"bismuth tripotassium dicitrate","genericName":"bismuth tripotassium dicitrate","slug":"bismuth-tripotassium-dicitrate","indication":"Other","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Vancomycin capsules","genericName":"Vancomycin capsules","slug":"vancomycin-capsules","indication":"Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA","status":"phase_3"},{"name":"Vancomycin oral liquid","genericName":"Vancomycin oral liquid","slug":"vancomycin-oral-liquid","indication":"Treatment of Clostridioides difficile infection","status":"phase_3"},{"name":"Fidaxomicin oral suspension","genericName":"Fidaxomicin oral suspension","slug":"fidaxomicin-oral-suspension","indication":"Clostridioides difficile infection (CDI), including initial and recurrent episodes","status":"phase_3"},{"name":"Fidaxomicin tablets","genericName":"Fidaxomicin tablets","slug":"fidaxomicin-tablets","indication":"Clostridioides difficile infection (CDI), including initial episode and recurrent infection","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"respiratory","drugs":[{"name":"ASP6294","genericName":"ASP6294","slug":"asp6294","indication":"Relapsing multiple sclerosis","status":"phase_2"},{"name":"ASP7962","genericName":"ASP7962","slug":"asp7962","indication":"Relapsing multiple sclerosis","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ASP8232","genericName":"ASP8232","slug":"asp8232","indication":"Treatment of autoimmune diseases","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"ASP8477","genericName":"ASP8477","slug":"asp8477","indication":"Relapsed or refractory non-Hodgkin lymphoma","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"rare","drugs":[{"name":"Locobase® REPAIR","genericName":"Locobase® REPAIR","slug":"locobase-repair","indication":"Dry skin and skin barrier dysfunction","status":"marketed"}]}],"pipeline":[{"name":"Evrenzo","genericName":"ROXADUSTAT","slug":"roxadustat","phase":"marketed","mechanism":"Thyroid hormone receptor beta","indications":["Anemia in chronic kidney disease","Refractory anemia (clinical)"],"catalyst":""},{"name":"ASP1707 single dose fed","genericName":"ASP1707 single dose fed","slug":"asp1707-single-dose-fed","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP8232","genericName":"ASP8232","slug":"asp8232","phase":"phase_2","mechanism":"ASP8232 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Treatment of autoimmune diseases"],"catalyst":""},{"name":"ASP8477","genericName":"ASP8477","slug":"asp8477","phase":"phase_2","mechanism":"ASP8477 is a small molecule that targets the CDK9 protein.","indications":["Relapsed or refractory non-Hodgkin lymphoma"],"catalyst":""},{"name":"Vancomycin capsules","genericName":"Vancomycin capsules","slug":"vancomycin-capsules","phase":"phase_3","mechanism":"Vancomycin inhibits cell wall synthesis in Gram-positive bacteria by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","indications":["Treatment of infections caused by susceptible Gram-positive bacteria, including MRSA"],"catalyst":""},{"name":"Vancomycin oral liquid","genericName":"Vancomycin oral liquid","slug":"vancomycin-oral-liquid","phase":"phase_3","mechanism":"Vancomycin oral liquid inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall precursors.","indications":["Treatment of Clostridioides difficile infection","Treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections"],"catalyst":""},{"name":"ASP1128","genericName":"ASP1128","slug":"asp1128","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 multiple dose of dose levels 1-2","genericName":"ASP1707 multiple dose of dose levels 1-2","slug":"asp1707-multiple-dose-of-dose-levels-1-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 multiple dose of dose levels 1-4","genericName":"ASP1707 multiple dose of dose levels 1-4","slug":"asp1707-multiple-dose-of-dose-levels-1-4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 single dose fasted","genericName":"ASP1707 single dose fasted","slug":"asp1707-single-dose-fasted","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP1707 single dose of dose levels 1 -7","genericName":"ASP1707 single dose of dose levels 1 -7","slug":"asp1707-single-dose-of-dose-levels-1-7","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP3652","genericName":"ASP3652","slug":"asp3652","phase":"phase_2","mechanism":"ASP3652 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","indications":["Complement-mediated inflammatory disorders (Phase 2 development)"],"catalyst":""},{"name":"ASP6282","genericName":"ASP6282","slug":"asp6282","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6294","genericName":"ASP6294","slug":"asp6294","phase":"phase_2","mechanism":"ASP6294 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"ASP6294 Intravenous","genericName":"ASP6294 Intravenous","slug":"asp6294-intravenous","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6294 Subcutaneous","genericName":"ASP6294 Subcutaneous","slug":"asp6294-subcutaneous","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP6858","genericName":"ASP6858","slug":"asp6858","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP7713","genericName":"ASP7713","slug":"asp7713","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ASP7962","genericName":"ASP7962","slug":"asp7962","phase":"phase_2","mechanism":"ASP7962 is a small molecule inhibitor of the PI3K delta subunit.","indications":["Relapsing multiple sclerosis"],"catalyst":""},{"name":"Fidaxomicin oral suspension","genericName":"Fidaxomicin oral suspension","slug":"fidaxomicin-oral-suspension","phase":"phase_3","mechanism":"Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora.","indications":["Clostridioides difficile infection (CDI), including initial and recurrent episodes"],"catalyst":""},{"name":"Fidaxomicin tablets","genericName":"Fidaxomicin tablets","slug":"fidaxomicin-tablets","phase":"phase_3","mechanism":"Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, selectively killing Clostridioides difficile while minimizing effects on normal gut flora.","indications":["Clostridioides difficile infection (CDI), including initial episode and recurrent infection"],"catalyst":""},{"name":"Locobase® REPAIR","genericName":"Locobase® REPAIR","slug":"locobase-repair","phase":"marketed","mechanism":"Locobase® REPAIR is an emollient and skin barrier repair product that restores skin hydration and protects damaged skin through occlusive and humectant ingredients.","indications":["Dry skin and skin barrier dysfunction","Symptomatic relief of xerosis and atopic dermatitis-prone skin"],"catalyst":""},{"name":"Placebo to match mirabegron","genericName":"Placebo to match mirabegron","slug":"placebo-to-match-mirabegron","phase":"phase_3","mechanism":"This is an inert placebo formulation designed to match the physical and sensory characteristics of mirabegron for blinded clinical trial purposes.","indications":["Placebo control for mirabegron trials in overactive bladder"],"catalyst":""},{"name":"Placebo to match solifenacin succinate","genericName":"Placebo to match solifenacin succinate","slug":"placebo-to-match-solifenacin-succinate","phase":"phase_3","mechanism":"This is a placebo formulation designed to match the appearance and administration of solifenacin succinate for blinded clinical trial purposes.","indications":["Placebo control for solifenacin succinate trials in overactive bladder"],"catalyst":""},{"name":"bismuth tripotassium dicitrate","genericName":"bismuth tripotassium dicitrate","slug":"bismuth-tripotassium-dicitrate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOcGZkcXZWcFhJUUxES0NqYUZlY0RSSS1JdzBZVGR6Y29MVnk1bkU3VzA4eU80UHlLV0hCUzlzVlRySmRXamI2VzB5MEV2Y2MySDVrQzIwWFdyeGN2WWhQZzZ4bFIwUUNUTjN4YkZPVTBTVFl0WldwV2dCaHpMY2tROE0wSjg4Wnh0dzBrODhnZmNtWG1aTUoxMkVBcXdiME0yX3FGVEl0U0JnRFU3d0FnYXI3cHlnTVEwNnUxbFBJWi1jNHFaWlE?oc=5","date":"2026-03-19","type":"regulatory","source":"Cape Times","summary":"SCA ruling ensures affordable Enzutrix remains accessible for prostate cancer patients - Cape Times","headline":"SCA ruling ensures affordable Enzutrix remains accessible for prostate cancer patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNZlVqUnE3VGQ1SlBqMHprajZmUUc3YkgxN3EtZTNHbW50MTZidmJQdG5DM2hRT1BMVFVOaHMxdC1Pd3pUVFhlQVA4eGx6cERZVXFxZ1VnTXJUVEJJQVh4SWJ3Y21nSXpuY29GdU9RWFVNck5hN2lMQXNfVVhiTWpMOVo5NGk2dmpRQThLYVJCbjhmb3JZR3hpM2pJZzROLTZ1dnJ6MktHWTNpMld6ODEwajFxTE0wel8x?oc=5","date":"2024-10-15","type":"pipeline","source":"European Medical Journal","summary":"Astellas’ Martina Dempsey on achieving equal footing for women in pharma - European Medical Journal","headline":"Astellas’ Martina Dempsey on achieving equal footing for women in pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRnlIVGdXdUFlUWNQR2NBVTl3VUJMVUJOTW10emJla1d2MVhXVUFqVEp2UXNOdzZnVTZmVm04RjJfNldZSEtVa1ZibUVObldfVzcxR2p4dF9nR2NqZVMxdTd0MmUtZGxrSnpvZ0tkRHFlazhEMlVycGNlMHF1N2ZqZkE5Y1NCRFdULUN0SW1nR29HdHBjZUVrMW9SY2hrbmJvSzB6WEhHQVM2UlBxX0Rxb0dZb0FIVkxN?oc=5","date":"2024-10-09","type":"deal","source":"European Biotechnology Magazine","summary":"AviadoBio Ltd inks US$2.2bn gene therapy deal with Astellas Pharma Inc - European Biotechnology Magazine","headline":"AviadoBio Ltd inks US$2.2bn gene therapy deal with Astellas Pharma Inc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1GOEdLZDRBS0RwRVY3bmlqZW1mZWxFMUZ2UkNQMnlUcDlRMUJ4VXdPaGtPM0FiWmhlYWJzeXlkVE5JaDVncm1pM2hQYTFPWVBOVk8wUDc0cWdxMXpMRlNzT2FCaE1wTHBLdkxR?oc=5","date":"2024-09-18","type":"regulatory","source":"Wiley Online Library","summary":"The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review - Wiley Online Library","headline":"The role of cardiac acoustic biomarkers in monitoring patients with heart failure: A systematic literature review","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQZ0ZGeE9lbFpqcVpvZzlTWUVPUGpCbWRnMlNFbGVVeGxRbm01cElCdTRRNWhPNjk2cm1HU1V6WG5INnNqS0F3Z3hlSkF2WUprTExDMmhvZ3pBTHl1cXdnUmhDZXhfN1hMdVk5UFlxWlFfOVg4SjF1b1I2cjBnMGtOX3hjWnN1NWI3b1pzTXQ0OFRrRVZwTDJRelh6ZXItdw?oc=5","date":"2024-04-29","type":"pipeline","source":"Pharmaceutical Technology","summary":"Astellas Pharma’s Aseptic Drug Product Manufacturing Facility, Ireland - Pharmaceutical Technology","headline":"Astellas Pharma’s Aseptic Drug Product Manufacturing Facility, Ireland","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNN0xldWtiblJKaXNZbGhZZkZyVHhYbFlvTUo4N0M3Qk9LUGtTYXZLMzczamNRclp6LWEtSk9WNmxnWm14S09GbmlMN3JqcEVqd0dtOVlxRk9VSVFndG1idkJZUVYyMnVKSzR4WGdycTZvYXUxMmhzYWlIeTQ1djFjR1BvMGdrS2p6cHBWMWtIb1hWU3EwMVJ3Ynd4T0Y3eTZ4Yldz?oc=5","date":"2024-04-09","type":"deal","source":"European Pharmaceutical Review","summary":"CDMO acquires Meppel facility from Astellas - European Pharmaceutical Review","headline":"CDMO acquires Meppel facility from Astellas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOS2ZuMmhQY0t2SWpSU25PZTRQWGJYM01SWnZDOTl6WFFONjBKQ19QUUZvMGplU0xzYVFuUkJtX0FBOHR6bE9JX1psOTlBMndBekQwdXV0MkJXbENRdEQ5Q1o3M0pPZW1yRGJuWnlNV2pHRk1MbTVrNFRoQXdPQk5GaUlhX2NjWnBueGVEWVphYjVuTEFxTDR3OWZaSE9xZGJ2ZVdVOWhzZWVXSUlPamlxbQ?oc=5","date":"2023-05-25","type":"pipeline","source":"BioPharm International","summary":"Astellas Pharma to Transfer Manufacturing Plant, Business to Delpharm - BioPharm International","headline":"Astellas Pharma to Transfer Manufacturing Plant, Business to Delpharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxQUUVNMkNGeEdsQ05FdEczQXhhbVlNd3BHdzdyWTVDVFZmcTJyaG5oRnVOZTl3TU9ad2hBeWhLWWVlU0tlM25hczVmU21LdWxNbndyV2ZBb0VTUlRVLUJGRWlSZzNmeG1ESU04Z2dueWVPS2lycmdlV2Z3U3FmRS1ncXFPWGRRU2RjZXFZNW1meVZWVThLYmpFc0UzUkt3d0xwajREX3dxQQ?oc=5","date":"2023-02-08","type":"pipeline","source":"BioSpectrum Asia","summary":"Astellas Pharma announces change of President and CEO - BioSpectrum Asia","headline":"Astellas Pharma announces change of President and CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQbG1RMzlYb0hTU0g1c2NGckNha2VaZldpRnE2UFJPNlZSQllhdFozaUM4MXJaaEJ0MkZuN3V6Q0pLbnFLMkFCUDlqZ2pTVkxzcHY3ejRhLUp5UmViR2xkQWVFaGVpZ3E1U2twQnRISVBOV0tHZFBJdFhJem1PY0dQR3MxUm14WEVWb0FqRl9MY0tjNjB0NDhxMWpwTU9aN0pzbUo0QWVoM3RkSExzWHNQaEgwdlliLTdmZGNpQzhaU1M0Z085cHc?oc=5","date":"2023-02-05","type":"pipeline","source":"PR Newswire","summary":"Astellas Announces Change of President and CEO and Management Structure - PR Newswire","headline":"Astellas Announces Change of President and CEO and Management Structure","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPdWQzU1ZiNlV6ZlhheXdaOFEzYmwyUnlGcDBMYnN3WVBKemhaOGJEQXF3VGdfVktCamxOWWxxRFdpbTB4eVBBbnZRU1d2QnNKUDNRS1RVTXlOeWdWb1JDSW8tckExR2dnLXJ3MW1EVEh0QzM4Nkg0NXpwUmREREhRUkhTZ2x0RlYzS3I3NEFqMWlqbGZjbVY5LXNwSU4wR3V5aHBrcTdobERXMVZTQkhpTVlLMm5ZaG9uQjRza1BIOXlYMUhUWXdMVVp3M1FIVHJFS2Zr?oc=5","date":"2021-04-15","type":"regulatory","source":"pharmaphorum","summary":"Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation - pharmaphorum","headline":"Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPRGd5ZUZBME9QQUVLZ2NSM3ctSm5MMWFLLV9xTUtKTnV5OUNOZmVVbkdjZTN4UWJkZmIwRzYyb09mbzRzbzBTSkJkYlB1UkRyRnByRFRUSUdiZnIwaUkyTHNHZC04Y0FNaFdzbXZ3RWhxZjk0NC1xNm5Pd1pIaXRPdXBfdE1QQkNwMVBHVVV5TGgxOVVDclZMWjNNeTkyTWFDc0JPVGdqR0hsNUxYNEFZaENQSlVKZw?oc=5","date":"2018-07-18","type":"pipeline","source":"Bloomberg.com","summary":"Astellas Is Considering Selling Europe Assets to Raise Cash - Bloomberg.com","headline":"Astellas Is Considering Selling Europe Assets to Raise Cash","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9sS3ZKYUI5UGdRLWc4YmxBMjFzTjE2SnE3ZERNTFlqaFYxRE12WTVMZ05LMDFNQU5ZYzR4eXV1bmZqUUNxdGcwNUhja2xCMFd3SEhBRlZXcDVSY0JwQ254M1pWVzBUR1ZBLXZpWA?oc=5","date":"2011-07-26","type":"pipeline","source":"Pharma Voice","summary":"Talent Pool - Pharma Voice","headline":"Talent Pool","sentiment":"neutral"}],"patents":[],"drugCount":25,"phaseCounts":{"marketed":3,"phase_1":10,"phase_2":6,"phase_3":6},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}